Xoma Royalty Acquires Gene Therapy Developer Generation Bio for $4.29 Per Share
Key Insights
Xoma Royalty (search) has agreed to acquire Generation Bio, a struggling gene therapy developer, for approximately $4.29 per share in its latest "zombie biotech" acquisition.
Generation Bio raised $200 million in its 2020 IPO to develop lipid nanoparticle-based gene therapy technology but faced setbacks including disappointing preclinical results and workforce reductions.
The acquisition includes contingent value rights for shareholders, potentially providing additional payments from cash holdings, lease savings, Moderna partnership milestones, and proceeds from delivery technology sales.
Xoma Royalty (search) has agreed to acquire Generation Bio, a gene therapy developer currently valued below its cash holdings, for approximately $4.29 per share in a deal announced late Monday. The acquisition represents the latest in Xoma's strategy of purchasing struggling biotechnology companies, often referred to as "zombie biotechs."
Deal Structure and Shareholder Benefits
The per-share acquisition price falls below Generation Bio's Monday closing price of $5.39, but shareholders will receive contingent value rights that could provide additional compensation. These rights include potential payments from cash on hand exceeding $29 million at closing, savings from a Generation office lease, milestone payments from the company's licensing partnership with Moderna, and proceeds from any future sale of Generation's delivery technology platform.
Generation Bio's board of directors unanimously approved the transaction, which follows the company's recent strategic difficulties and workforce reductions.
Generation Bio's Journey from IPO to Acquisition
Generation Bio raised $200 million in its 2020 initial public offering during a period of significant investor interest in gene and cell therapy developers. The company aimed to advance next-generation gene therapy technology using lipid nanoparticles rather than engineered viruses to deliver genetic cargo.
However, the company faced significant challenges following its public debut. Shares plummeted after disappointing preclinical study results delayed development timelines in 2021. Despite forming a partnership with Moderna, Generation Bio was forced to lay off 40% of its staff and streamline research operations amid a strategic shift.
Recent Developments and Workforce Reduction
In August, Generation Bio presented data suggesting its technology could deliver RNA medicines into T cells. However, the company simultaneously eliminated 90% of its workforce and initiated a strategic review, citing the early-stage nature of its technology and the lengthy development path ahead. The company's longtime CEO transitioned to board chair following these changes.
Xoma's Acquisition Strategy
Generation Bio fits the profile of companies Xoma has targeted in its recent acquisition spree. Since 2024, Xoma has pursued bids for several struggling biotechnology companies, including Turnstone Biologics, Mural Oncology, HilleVax, and Lava Therapeutics.
Xoma CEO Owen Hughes described this strategy as providing struggling companies an opportunity to "do the right thing" by shareholders and return invested capital. The approach focuses on acquiring companies that are trading below their asset values and face significant development challenges.
Analyst Perspective
Jefferies (search) analyst Farzin Haque noted that while Generation Bio possesses "a diverse set of assets" with strong intellectual property protection, all of its programs "will require substantial work" to achieve proof-of-concept in humans and "get any value" from an acquirer. Haque described the deal structure as "attractive given the circumstances."